Medscape is available in 5 Language Editions – Choose your Edition here.


Retroperitoneal Lymph Node Dissection Treatment & Management

  • Author: Jared M Whitson, MD; Chief Editor: Bradley Fields Schwartz, DO, FACS  more...
Updated: Sep 21, 2015

Surgical Therapy

Clinical stage I disease

Recent National Comprehensive Cancer Network Guidelines recommend surveillance (in compliant patients only), nerve-sparing retroperitoneal lymph node dissection (RPLND), or chemotherapy (IB) for patients with stage I NSGCT.[36] For those patients who choose RPLND over surveillance, ipsilateral modified nerve-sparing RPLND can be performed. If minimal retroperitoneal disease is discovered, the surgeon may choose to perform a full ipsilateral dissection, although nerve-sparing is still likely to be performed.

The development of advanced laparoscopic techniques has provided the opportunity to perform laparoscopic RPLND (L-RPLND), both template and nerve-sparing. However, debate persists regarding whether L-RPLND is merely a diagnostic staging procedure or yields cancer control comparable to that of open RPLND in the 30% of patients with pathologic stage II disease. The nodal count possible with L-RPLND and the adherence to the template format are persistent questions. Research is ongoing as to the appropriate threshold number of nodes removed for diagnostic and therapeutic efficacy.[37]

A review of the literature identified 333 patients who underwent L-RPLND for stage I disease.[38] Positive nodes were found in 22% of patients, 97% of whom received adjuvant chemotherapy. Only a 0.3% incidence of retroperitoneal recurrence occurred, again with the caveat that the vast majority of patients with pathologic stage II disease received chemotherapy.

Clinical stage II disease

Patients with low-volume stage II disease who undergo primary RPLND are also candidates for ipsilateral modified nerve-sparing RPLND. Candidates for primary RPLND include patients with normal tumor marker levels, adenopathy smaller than 2 cm in diameter within the primary landing zone, and the absence of multiple enlarged lymph nodes.[39] However, in this case, if the clinical stage is underestimated and high-volume stage II disease is detected, the surgeon should perform a full ipsilateral dissection. Once again, the sympathetic nerves can be prospectively identified and preserved.

Many patients with clinical stage IIB disease who undergo initial chemotherapy have residual retroperitoneal masses and require salvage RPLND. Recently, both Janetschek et al[40] and Kavoussi[41] reported series of patients in whom L-RPLND in this setting was successful. A recent review of the literature identified 117 patients who underwent L-RPLND in the setting of clinical stage II disease or postchemotherapy.[38] Viable NSGCT was found in 6.8%, with teratoma identified in 23%. Recurrence occurred in 5.1% of patients, with the location of recurrence not reported in most instances. A single institution reported very similar results on 100 patients, in whom 1 recurrence occurred and 100% disease-specific survival was seen at 5-years median follow-up.[42]

Clinical stage IIc/III disease

Patients with residual masses following chemotherapy for advanced disease usually require standard RPLND with full bilateral dissection from the crura of the diaphragm to below the aortic bifurcation. Proponents of this method argue that 7-32% of patients will have tumor or teratoma outside a modified template, with decreasing percentages associated with decreased prechemotherapy clinical staging.[43] In initial experience, Rassweiller et al found a high open conversion rate with postchemotherapy L-RPLND.[44]


Preoperative Details

Preoperative preparation for RPLND involves obtaining informed consent and arranging a mechanical bowel preparation. Type and crossmatch for possible blood transfusion, especially in preparation for complex RPLND. In patients exposed to chemotherapy, WBC and platelet counts should be within the reference range or stabilized prior to surgery. Preoperatively evaluate patients receiving bleomycin with pulmonary function testing. Preoperatively evaluate patients with comorbid disease presentations (eg, renal insufficiency, anemia, heart conditions, liver pathology) with the appropriate consultations and/or laboratory studies.

Patients who have received bleomycin as a component of chemotherapy should probably undergo pulmonary function testing to evaluate for restrictive pulmonary fibrosis. Low inspired oxygen levels were once recommended during surgery; however, the most predictive factors for pulmonary complications include transfusion and total intravenous fluids.[45] Therefore, fluids must be limited to the greatest degree possible during and after surgery.


Intraoperative Details

From the time of its inception, RPLND has undergone many modifications and enhancements. Today, the two most popular approaches are the transabdominal and thoracoabdominal techniques. A laparoscopic alternative to the open procedure has been reported, but is limited to a few centers in the United States and Europe with significant laparoscopic experience.

The thoracoabdominal approach offers good exposure to the upper retroperitoneum and exposes the renal hilum in the center of the operating field. This procedure is useful in patients with advanced disease, who may present with a large retroperitoneal mass. This approach also allows for a complete suprahilar dissection, as well as the opportunity to easily access the retrocrural lymph nodes. Another advantage of this approach for RPLND is that it can be performed completely extraperitoneally in patients with lower-stage disease. This decreases the risks of small-bowel obstruction and ileus.

The second most common approach to RPLND is the transabdominal incision. This modification allows for faster opening and closing time. Additionally, this approach allows for good exposure to the suprahilar region, at the expense of mobilization of the pancreas and spleen. Advantages of a midline transperitoneal approach include familiarity and comfort for the surgeon and tolerable morbidity for the patient.

Currently, at the authors' institution, L-RPLND is used for select patients with low-stage disease. The procedure mimics the open operation in order to obtain similar oncologic and functional outcomes. A 4-port, transperitoneal technique is used, similar to that for laparoscopic nephrectomy. The authors perform a modified template operation with prospective nerve-sparing, adhering to the boundaries for each side outlined below. Intraoperative frozen-section analysis of the lymphatic tissue is used to determine whether the dissection is carried out to extended boundaries or an open conversion is necessary.

Right-sided modified template primary retroperitoneal lymph node dissection

The limits of dissection for the modified template RPLND on the right side include the right ureter, the renal veins, the lateral edge of the aorta, the IMA, and the ipsilateral iliac artery, where the ureter crosses. Note that the interaortocaval and retrocaval tissue is completely removed.

Limited right-sided retroperitoneal lymph node dis Limited right-sided retroperitoneal lymph node dissection (boundaries of dissection indicated by yellow border).

Left-sided modified template primary retroperitoneal lymph node dissection

The limits of dissection for the modified template RPLND on the left side include the left ureter, left renal vein, left edge of vena cava, IMA, and ipsilateral iliac artery, where the ureter crosses. Again, the interaortocaval tissue is included with the retroaortic lymphatics.

Limited left-sided retroperitoneal lymph node diss Limited left-sided retroperitoneal lymph node dissection (boundaries of dissection indicated by yellow border).

Postchemotherapy retroperitoneal lymph node dissection

Postchemotherapy RPLND typically entails full bilateral dissection of retroperitoneal lymphatics. This procedure involves removal of lymphatic tissue between both ureters, spanning from the diaphragmatic crus to the bifurcation of the common iliac arteries. The rationale for this extended region of dissection is the greater likelihood of bilateral disease with greater tumor burden. However, some patients with smaller-volume, localized disease within the primary landing site may be candidates for less-extensive RPLND.

Full right-sided retroperitoneal lymph node dissec Full right-sided retroperitoneal lymph node dissection (boundaries of dissection indicated by yellow border).
Full left-sided retroperitoneal lymph node dissect Full left-sided retroperitoneal lymph node dissection (boundaries of dissection indicated by yellow border).

Postoperative Details

Provide routine postoperative care. Patients should receive an appropriate amount of intravenous fluid replacements for the first 24-48 hours because of third-spacing.

Postoperative ileus is minimized with the retroperitoneal approach, and most patients are discharged within 3-6 days. If ileus is encountered, institute nasogastric suction for several days until symptoms resolve.

The pulmonary function in patients undergoing postchemotherapy RPLND should be closely monitored since they may have received bleomycin. Minimizing inspired oxygen concentration and intravenous fluids limits the risk of respiratory distress.



All patients with testicular cancer, regardless of stage, require frequent follow-up care. Many different follow-up protocols exist, and they vary depending on the clinical and pathologic stage and whether the patient is on a surveillance, post-RPLND, or post-chemotherapy protocol.

Most protocols involve history taking, physical examination (including examination of the contralateral testis), assessment of serum tumor markers, chest radiography, and abdominal imaging. After RPLND, postoperative baseline CT scanning, along with chest radiography, examinations, and assessment of serum tumor markers, is recommended every 2-3 months for the first 2 years, every 4 months for the subsequent 2 years, every 6 months for the fifth year, and yearly thereafter.



Complications of retroperitoneal lymph node dissection (RPLND) vary widely and can include injuries to major vascular structures such as the aorta and vena cava; to solid organs including the liver, kidney, and pancreas; and to smaller tubular structures such as the ureters and cisterna chyli.

Most of these injuries can be managed with primary repair and conservative management, which may include placement of a nephrostomy tube or ureteral stent, prolonged drainage of lymphatic fluid, and modified low-fat diets.

The overall complication rates of primary RPLND and postchemotherapy RPLND vary but probably lie between 1% and 5% for major complications and around 15% for minor complications (eg, wound infection, urinary tract infection, ileus).

  • Chylous ascites - 1-3%
  • Renovascular injury - 1-3%
  • Small-bowel obstruction - 1-3%
  • Spinal cord ischemia - Less than 1%

Outcome and Prognosis

The survival rate among patients with testicular cancer who undergo retroperitoneal lymph node dissection (RPLND) has improved significantly since the early 1980s. All stages are associated with a cure rate of at least 90%. Stages I, IIA, and IIB are associated with a 98-100% cure rate. Stages IIC and III have a response rate of approximately 90% with chemotherapy and RPLND, with an 86% durable response rate.

Investigators generally agree that the presence of mediastinal primary tumor and metastasis to visceral sites indicates a poor prognostic outcome. Significantly elevated levels of the tumor serum markers are thought to be a significant independent predictor of poor outcome.


Future and Controversies

Progress in the management of testicular cancer has resulted from a multimodal treatment strategy, yielding excellent oncologic outcomes in most men with the disease. Despite the advances in chemotherapy and the ability to assess risk in patients with low clinical stage, surgical therapy, involving removal of retroperitoneal lymph nodes, continues to play a crucial role in management algorithms for low-stage to advanced cases and for all histologic subtypes, including nonseminomatous germ cell tumors (NSGCTs) and seminoma.

The surgical techniques of retroperitoneal lymph node dissection (RPLND) have evolved. In patients with low-clinical-stage NSGCT, the preservation of ejaculatory function has minimized morbidity, while oncologic efficacy has been maintained through meticulous removal of all lymphatic tissue within the desired boundaries.

Currently, the inaccuracy of clinical staging and selection of appropriate therapy in patients with low-stage NSGCT is controversial. For example, testis-confined tumors (pathologic stage I) may be indistinguishable from occult microscopic stage II/III disease; approximately 30% of retroperitoneal disease cases are not categorized as such using initial imaging studies. Conversely, 70% of patients who undergo RPLND for clinical stage I disease are overtreated.

Presently, the most useful prognostic factors in risk stratification of low-clinical-stage NSGCT include the percentage of embryonal carcinoma and presence or absence of lymphatic/vascular invasion by tumor cells in the primary tumor. In the future, oncogene markers, tumor-suppressor gene markers,[46] flow cytometry,[47, 48] and advanced imaging modalities may play an important role in more accurately predicting true stage in patients with clinical stage I disease.[49] The prediction of a response to chemotherapy based on the expression of multidrug resistance protein 1 (MDR1) efflux pump has recently showed a trend toward significance.[50] Should L-RPLND prove to be as accurate and useful as the traditional open RPLND approach, the reduced morbidity of L-RPLND may shift more patients toward surgical intervention, away from either initial surveillance or chemotherapy. Nevertheless, L-RPLND remains technically challenging and requires further study and refinement.

Whether robotic-assistance facilitates more widespread implementation of the laparoscopic approach remains to be determined.

A single institution study evaluated outcomes of the first 18 patients treated with robot-assisted retroperitoneal lymph node dissection for non-seminomatous germ cell tumors (NSGCT) and paratesticular rhabdomyosarcoma (RMS). The study reported that this initial selected case series shows that the procedure is safe, reproducible, and feasible for stage I-IIB NSGCT and RMS in the hands of experienced robotic surgeons although the authors added that larger studies are needed to confirm the diagnostic and therapeutic utility of this technique.[51]

Although contemporary postchemotherapy RPLND has attained a higher success rate, it still is a relatively morbid procedure. The operation is best performed via an open incision and requires wide exposure of the retroperitoneal structures. Careful and extensive removal of lymph nodes is balanced against potential injury to major vascular structures and organs such as the kidneys and ureters. In the future, methods of differentiating fibrosis and scar from viable germ cell tumor and/or teratoma after chemotherapy may spare some patients RPLND.

Further improvements in the management of testicular cancer may result from better selection of patients with low-stage and high-stage disease for adjuvant therapy. RPLND remains an integral part of all treatment approaches and has a role in staging and cure in those with low-stage disease; in addition, it can be used effectively to treat teratoma and germ cell tumor in patients with advanced disease after systemic therapy.

Contributor Information and Disclosures

Jared M Whitson, MD Urologic Oncologist, Department of Urology, Kaiser-Permanente South Sacramento Medical Center

Jared M Whitson, MD is a member of the following medical societies: American Association for Cancer Research, American College of Surgeons, American Medical Association, American Urological Association, Endourological Society, American Society of Clinical Oncology

Disclosure: Nothing to disclose.


Maxwell Meng, MD Associate Professor-in-Residence, Department of Urology, University of California, San Francisco, School of Medicine

Maxwell Meng, MD is a member of the following medical societies: American College of Surgeons, American Urological Association, Society of Urologic Oncology

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

Bradley Fields Schwartz, DO, FACS Professor of Urology, Director, Center for Laparoscopy and Endourology, Department of Surgery, Southern Illinois University School of Medicine

Bradley Fields Schwartz, DO, FACS is a member of the following medical societies: American College of Surgeons, Society of Laparoendoscopic Surgeons, Society of University Urologists, Association of Military Osteopathic Physicians and Surgeons, American Urological Association, Endourological Society

Disclosure: Nothing to disclose.


Jong M Choe, MD, FACS †, Former Assistant Professor, Department of Surgery, Division of Urology, University of Cincinnati College of Medicine, Former Director of Continence and Urodynamic Center, Mount Vernon Urological Associates, LLC

Disclosure: Nothing to disclose.

Rajesh Prasad, MD, Staff Physician, Department of Surgery, Division of Urology, University of Cincinnati Medical Center

Disclosure: Nothing to disclose.

Dan Theodorescu, MD, PhD Paul A Bunn Professor of Cancer Research, Professor of Surgery and Pharmacology, Director, University of Colorado Comprehensive Cancer Center

Dan Theodorescu, MD, PhD is a member of the following medical societies: American Cancer Society, American College of Surgeons, American Urological Association, Medical Society of Virginia, Society for Basic Urologic Research, and Society of Urologic Oncology

Disclosure: Key Genomics Ownership interest Co-Founder-50% Stock Ownership; KromaTiD, Inc Stock Options Board membership

  1. ROBSON CJ. Radical nephrectomy for renal cell carcinoma. J Urol. 1963 Jan. 89:37-42. [Medline].

  2. Blom JH, van Poppel H, Marechal JM, Jacqmin D, Sylvester R, Schröder FH, et al. Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. EORTC Genitourinary Group. Eur Urol. 1999 Dec. 36(6):570-5. [Medline].

  3. Chapman TN, Sharma S, Zhang S, Wong MK, Kim HL. Laparoscopic lymph node dissection in clinically node-negative patients undergoing laparoscopic nephrectomy for renal carcinoma. Urology. 2008 Feb. 71(2):287-91. [Medline].

  4. Simmons MN, Kaouk J, Gill IS, Fergany A. Laparoscopic radical nephrectomy with hilar lymph node dissection in patients with advanced renal cell carcinoma. Urology. 2007 Jul. 70(1):43-6. [Medline].

  5. Brausi MA, Gavioli M, De Luca G, Verrini G, Peracchia G, Simonini G, et al. Retroperitoneal lymph node dissection (RPLD) in conjunction with nephroureterectomy in the treatment of infiltrative transitional cell carcinoma (TCC) of the upper urinary tract: impact on survival. Eur Urol. 2007 Nov. 52(5):1414-8. [Medline].

  6. Jamieson JK, Dobson JF. The lymphatics of the testicle. Lancet. 1910. 1:493.

  7. Rouvier H. Lymphatic system of. the abdomen and pelvis. Anatomy of the human lymphatic system. 1938.

  8. Hinman F, Gibson TE, Kutzmann AA. Radical operation for teratoma testis. Surg Gynecol Obstet. 1923. 37:429-451.

  9. Cooper JF, Leadbetter WH, Chute R. The thoracoabdominal approach for retroperitoneal lymph node dissection: Its application to testis tumors. Surg Gynecol Obstet. 1950. 90:486.

  10. Busch FM, Sayegh ES, Chenault OW Jr. Some uses of Lymphangiography in the Management of testicular tumors. J Urol. 1965 Apr. 93:490-5. [Medline].

  11. Chiappa S, Uslenghi C, Bonadonna G, Marano P, Ravasi G. Combined testicular and foot lymphangiography in testicular carcinomas. Surg Gynecol Obstet. 1966 Jul. 123(1):10-4. [Medline].

  12. Skinner DG, Leadbetter WF. The surgical management of testis tumors. J Urol. 1971 Jul. 106(1):84-93. [Medline].

  13. Donohue JP. Retroperitoneal lymphadenectomy: the anterior approach including bilateral suprarenal-hilar dissection. Urol Clin North Am. 1977 Oct. 4(3):509-21. [Medline].

  14. Narayan P, Lange PH, Fraley EE. Ejaculation and fertility after extended retroperitoneal lymph node dissection for testicular cancer. J Urol. 1982 Apr. 127(4):685-8. [Medline].

  15. Richie JP. Clinical stage 1 testicular cancer: the role of modified retroperitoneal lymphadenectomy. J Urol. 1990 Nov. 144(5):1160-3. [Medline].

  16. Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R. Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. J Urol. 1993 Feb. 149(2):237-43. [Medline].

  17. Rukstalis DB, Chodak GW. Laparoscopic retroperitoneal lymph node dissection in a patient with stage 1 testicular carcinoma. J Urol. 1992 Dec. 148(6):1907-9; discussion 1909-10. [Medline].

  18. Janetschek G, Hobisch A, Peschel R. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous testicular carcinoma: long-term outcome. J Urol. 2000 Jun. 163(6):1793-6. [Medline].

  19. Peschel R, Gettman MT, Neururer R, Hobisch A, Bartsch G. Laparoscopic retroperitoneal lymph node dissection: description of the nerve-sparing technique. Urology. 2002 Aug. 60(2):339-43; discussion 343. [Medline].

  20. Williams SB, Lau CS, Josephson DY. Initial Series of Robot-Assisted Laparoscopic Retroperitoneal Lymph Node Dissection for Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer. Eur Urol. 2011 Mar 21. [Medline].

  21. Cresswell J, Scheitlin W, Gozen A, Lenz E, Teber D, Rassweiler J. Laparoscopic retroperitoneal lymph node dissection combined with adjuvant chemotherapy for pathological stage II disease in nonseminomatous germ cell tumours: a 15-year experience. BJU Int. 2008 Sep. 102(7):844-8. [Medline].

  22. Spermon JR, Witjes JA. Case report: the danger of postchemotherapy laparoscopic retroperitoneal lymph node dissection for nonseminomatous testicular carcinoma. J Endourol. 2008 May. 22(5):1013-6. [Medline].

  23. Kim P, Syan-Bhanvadia S, Djaladat H, Faber K, Tadros NN, Nichols C. Midline extraperitoneal approach for retroperitoneal lymph node dissection for testicular germ cell tumor. Urology. 2012 Oct. 80(4):941-5. [Medline].

  24. Nicolai N, Pizzocaro G. A surveillance study of clinical stage I nonseminomatous germ cell tumors of the testis: 10-year followup. J Urol. 1995 Sep. 154(3):1045-9. [Medline].

  25. Sogani PC, Perrotti M, Herr HW, Fair WR, Thaler HT, Bosl G. Clinical stage I testis cancer: long-term outcome of patients on surveillance. J Urol. 1998 Mar. 159(3):855-8. [Medline].

  26. Lashley DB, Lowe BA. A rational approach to managing stage I nonseminomatous germ cell cancer. Urol Clin North Am. 1998 Aug. 25(3):405-23. [Medline].

  27. Hoskin P, Dilly S, Easton D, Horwich A, Hendry W, Peckham MJ. Prognostic factors in stage I non-seminomatous germ-cell testicular tumors managed by orchiectomy and surveillance: implications for adjuvant chemotherapy. J Clin Oncol. 1986 Jul. 4(7):1031-6. [Medline].

  28. Heidenreich A, Sesterhenn IA, Mostofi FK, Moul JW. Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis. Cancer. 1998 Sep 1. 83(5):1002-11. [Medline].

  29. Steele GS, Richie JP. Current role of retroperitoneal lymph node dissection in testicular cancer. Oncology (Williston Park). 1997 May. 11(5):717-29; discussion 730-37 passim. [Medline].

  30. Swanson DA. Should chemotherapy replace retroperitoneal lymphadenectomy for clinical stage II testicular tumors?. Mayo Clin Proc. 1995 Sep. 70(9):911-3. [Medline].

  31. Stomper PC, Kalish LA, Garnick MB, Richie JP, Kantoff PW. CT and pathologic predictive features of residual mass histologic findings after chemotherapy for nonseminomatous germ cell tumors: can residual malignancy or teratoma be excluded?. Radiology. 1991 Sep. 180(3):711-4. [Medline].

  32. Donohue JP, Rowland RG. Complications of retroperitoneal lymph node dissection. J Urol. 1981 Mar. 125(3):338-40. [Medline].

  33. Loehrer PJ Sr, Hui S, Clark S, Seal M, Einhorn LH, Williams SD. Teratoma following cisplatin-based combination chemotherapy for nonseminomatous germ cell tumors: a clinicopathological correlation. J Urol. 1986 Jun. 135(6):1183-9. [Medline].

  34. Stephenson AJ, Bosl GJ, Bajorin DF, Stasi J, Motzer RJ, Sheinfeld J. Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion. J Urol. 2005 Aug. 174(2):557-60; discussion 560. [Medline].

  35. Beck SD, Foster RS, Bihrle R, Donohue JP, Einhorn LH. Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor?. Cancer. 2007 Sep 15. 110(6):1235-40. [Medline].

  36. [Guideline] Testicular Cancer Guideline v2.2011. Network NCC. Available at Accessed: 6/29/2011.

  37. Thompson RH, Carver BS, Bosl GJ, Bajorin D, Motzer R, Feldman D. Evaluation of lymph node counts in primary retroperitoneal lymph node dissection. Cancer. 2010 Nov 15. 116(22):5243-50. [Medline].

  38. Finelli A. Laparoscopic retroperitoneal lymph node dissection for nonseminomatous germ cell tumors: long-term oncologic outcomes. Curr Opin Urol. 2008 Mar. 18(2):180-4. [Medline].

  39. Stephenson AJ, Bosl GJ, Motzer RJ, Bajorin DF, Stasi JP, Sheinfeld J. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer. J Clin Oncol. 2007 Dec 10. 25(35):5597-602. [Medline].

  40. Albqami N, Janetschek G. Laparoscopic retroperitoneal lymph-node dissection in the management of clinical stage I and II testicular cancer. J Endourol. 2005 Jul-Aug. 19(6):683-92; discussion 692. [Medline].

  41. Bhayani SB, Ong A, Oh WK, Kantoff PW, Kavoussi LR. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer: a long-term update. Urology. 2003 Aug. 62(2):324-7. [Medline].

  42. Steiner H, Leonhartsberger N, Stoehr B, Peschel R, Pichler R. Postchemotherapy laparoscopic retroperitoneal lymph node dissection for low-volume, stage II, nonseminomatous germ cell tumor: first 100 patients. Eur Urol. 2013 Jun. 63(6):1013-7. [Medline].

  43. Carver BS, Shayegan B, Eggener S, Stasi J, Motzer RJ, Bosl GJ, et al. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol. 2007 Oct 1. 25(28):4365-9. [Medline].

  44. Rassweiler JJ, Frede T, Lenz E, Seemann O, Alken P. Long-term experience with laparoscopic retroperitoneal lymph node dissection in the management of low-stage testis cancer. Eur Urol. 2000 Mar. 37(3):251-60. [Medline].

  45. Donat SM, Levy DA. Bleomycin associated pulmonary toxicity: is perioperative oxygen restriction necessary?. J Urol. 1998 Oct. 160(4):1347-52. [Medline].

  46. Albers P, Orazi A, Ulbright TM, Miller GA, Haidar JH, Donohue JP, et al. Prognostic significance of immunohistochemical proliferation markers (Ki-67/MIB-1 and proliferation-associated nuclear antigen), p53 protein accumulation, and neovascularization in clinical stage A nonseminomatous testicular germ cell tumors. Mod Pathol. 1995 Jun. 8(5):492-7. [Medline].

  47. de Riese W, Walker EB, de Riese C, Ulbright TM, Crabtree WN, Messemer J, et al. Quantitative DNA measurement by flow cytometry and image analysis of human nonseminomatous germ cell testicular tumors. Urol Res. 1994. 22(4):213-20. [Medline].

  48. Moul JW, Foley JP, Hitchcock CL, McCarthy WF, Sesterhenn IA, Becker RL, et al. Flow cytometric and quantitative histological parameters to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors. J Urol. 1993 Sep. 150(3):879-83. [Medline].

  49. Foster RS, Nichols CR. Testicular cancer: what's new in staging, prognosis, and therapy. Oncology (Williston Park). 1999 Dec. 13(12):1689-94; discussion 1697-700, 1703. [Medline].

  50. Schrader AJ, Seger M, Konrad L, Olbert P, Hegele A, Hofmann R, et al. Clinical impact of MDR1-expression in testicular germ cell cancer. Exp Oncol. 2007 Sep. 29(3):212-6. [Medline].

  51. Cheney SM, Andrews PE, Leibovich BC, Castle EP. Robot-assisted retroperitoneal lymph node dissection: technique and initial case series of 18 patients. BJU Int. 2015 Jan. 115 (1):114-20. [Medline].

Limited right-sided retroperitoneal lymph node dissection (boundaries of dissection indicated by yellow border).
Limited left-sided retroperitoneal lymph node dissection (boundaries of dissection indicated by yellow border).
Full right-sided retroperitoneal lymph node dissection (boundaries of dissection indicated by yellow border).
Full left-sided retroperitoneal lymph node dissection (boundaries of dissection indicated by yellow border).
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.